Table 1.
Baseline characteristics of NSCLC patients assessed for tumor mutational burden
| Patient characteristics | All patients (n = 76) No (%) | TMB low and int (n = 51) No (%) | TMB high (n = 25) No (%) | P value |
|---|---|---|---|---|
| Age (years) | 0.907 | |||
| Median (range) | 66 (31–90) | 65 (49–79) | 67 (31–90) | |
| Sex (N) | 0.615 | |||
| Male | 47 (62) | 30 (59) | 16 (68) | |
| Female | 29 (38) | 21 (41) | 8 (32) | |
| Tumor histology at diagnosis (N) | >0.999 | |||
| Adenocarcinoma | 70 (92) | 47 (92) | 23 (92) | |
| Squamous cell carcinoma | 6 (8) | 4 (8) | 2 (8) | |
| Tumor type (N) | 0.043 | |||
| Primary tumor | 47 (62) | 36 (71) | 11 (44) | |
| Metastasis/lymph node | 29 (38) | 15 (29) | 14 (56) | |
| Tumor cell content (%) | 0.213 | |||
| Median (range) | 60 (20–95) | 60 (20–95) | 60 (20–90) | |
| Immunotherapy (N) | >0.999 | |||
| Nivolumab | 60 (79) | 40 (78) | 20 (80) | |
| Pembrolizumab | 10 (13) | 9 (18) | 1 (4) | |
| Atezolizumab | 3 (4) | 2 (4) | 1 (4) | |
| Other (Nivolumab + ipilimumab) | 3 (4) | 0 (0) | 3 (12) | |
| No of lines before I‐O (N) | 0.724 | |||
| First (0) | 11 (14) | 7 (14) | 4 (16) | |
| Second (1) | 39 (51) | 30 (59) | 9 (36) | |
| Third (2) | 10 (13) | 6 (12) | 4 (16) | |
| Fourth (3) | 2 (3) | 0 (0) | 2 (8) | |
| Not available | 13 (17) | 8 (16) | 5 (20) | |
| Smoking status (N) | 0.155 | |||
| Never | 10 (13) | 9 (18) | 1 (4) | |
| Current/former | 60 (79) | 39 (76) | 21 (84) | |
| Not available | 6 (8) | 3 (6) | 3 (12) | |
| PD‐L1 (N) | >0.999 | |||
| < 1% | 28 (37) | 19 (37) | 9 (36) | |
| ≥ 1% | 39 (51) | 27 (53) | 12 (48) | |
| Not available | 9 (12) | 5 (10) | 4 (16) | |
| Stage at diagnosis (N) | >0.999 | |||
| I–III | 25 (33) | 17 (33) | 8 (32) | |
| IV | 49 (64) | 32 (63) | 17 (68) | |
| Durable clinical benefit (N) | 0.013 | |||
| DCB | 32 (42) | 16 (31) | 16 (64) | |
| No DCB | 44 (58) | 35 (69) | 9 (36) |